{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-063539","form_type":"8-K","ticker":"RLAY","cik":"0001812364","company_name":"Relay Therapeutics, Inc.","filed_at":"2025-05-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.827837+00:00","generated_at":"2026-05-22T18:16:23.319627+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Relay Therapeutics Q1 net loss $77M; cash runway into 2029, RLY-2608 Phase 3 on track","bullets":["Net loss $77.1M ($0.46/share) vs $81.4M ($0.62/share) in Q1 2024; revenue $7.7M from Elevar license completion.","Cash $710.3M; runway extended into 2029, funding ReDiscover-2 past topline and vascular malformations proof-of-concept.","Phase 3 ReDiscover-2 trial of RLY-2608+fulvestrant in breast cancer on track for mid-2025; ASCO abstract accepted.","Initiated Phase 1 RLY-2608 vascular malformations trial in Q1 2025.","Reduced workforce by ~70; research run rate cut ~80%; out-licensed RLY-4008 to Elevar with downstream economics."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-063539","json":"https://secwatch.observer/filing/0000950170-25-063539.json","markdown":"https://secwatch.observer/filing/0000950170-25-063539.md","text":"https://secwatch.observer/filing/0000950170-25-063539.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1812364/000095017025063539/0000950170-25-063539-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1812364/000095017025063539/rlay-20250505.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T18:16:23.319627+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}